Regulatory 2024-01-24 | Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2023-11-13 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023 PDF Report Presentation Webcast
Regulatory 2023-11-09 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan PDF Report Presentation Webcast
Regulatory 2023-10-19 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2023-08-31 | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 PDF Report Presentation Webcast
Regulatory 2023-04-03 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2023-03-13 | Ascelia Pharma Mourns the Passing of Board Member René Spogárd PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
